OTC:CLCS
Cell Source, Inc.
A pre-revenue biotech firm advancing cell therapy platforms with a significant retained earnings deficit funded by substantial equity raises.
Key Metrics
Investment Thesis
Bull Case
Investors might buy CLCS for exposure to high-potential cell therapy technologies that could revolutionize cancer treatment if the clinical programs succeed. The recent $2.1M cash infusion from financing activities provides a temporary runway, though it is not sufficient to achieve long-term sustainability without revenue. A successful Phase II or III trial readout could trigger a significant re-rating of the stock based on commercial potential.
Bear Case
The stock is a high-risk speculative asset with zero revenue, a massive $41.7M deficit, and cash reserves nearly depleted to $22k. Continued negative operating cash flow of $2.3M suggests the company will likely require further dilution or risk insolvency if commercial milestones are not met immediately. The lack of current income and gross profit highlights the extreme financial fragility inherent in pre-revenue biotechnology firms.
About Cell Source, Inc.
Cell Source, Inc. (CLCS) is a biotechnology company focused on developing novel cell therapies and immunotherapies for the treatment of cancer and other diseases. The company operates primarily in the United States and internationally, leveraging proprietary technology platforms to advance clinical-stage programs. While recent financials show zero revenue, the firm relies on paid-in capital and financing activities to fund its high-risk R&D operations.
Analysis
Management Discussion
Recent annual performance reveals a net loss of $5.3M driven by $4.3M in operating expenses and general administrative costs, resulting in negative cash flow from operations of $2.3M. Although the company successfully raised $2.1M through financing activities, this was insufficient to offset burn, causing ending cash reserves to drop sharply from a beginning balance of $222k to just $22k. The company's financial health is critically dependent on continued access to equity markets and successful progression of its clinical pipeline.
Industry Overview
The cell therapy and immunotherapy sector is characterized by high R&D costs, long development timelines, and binary outcomes where failure at any stage can wipe out significant value. Companies in this space often trade with low liquidity on OTC markets due to the speculative nature of their asset-light business models. Success requires substantial venture capital or public market financing to bridge the gap between discovery and commercialization.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of Revenue | $0 | $0 |
| Gross Profit | $0 | $0 |
| Operating Expenses | $4.2M | $4.3M |
| Operating Income | $-4.2M | $-4.3M |
| R&D | $1.9M | — |
| G&A | $2.2M | $2.6M |
| Stock-Based Comp | $77.9K | $463.0K |
| Other OpEx | $58.0K | $1.7M |
| Non-Operating Income | $-992.4K | $-995.9K |
| Pre-Tax Income | $-5.2M | $-5.3M |
| Income Tax | $0 | $0 |
| Continuing Ops | $-5.2M | $-5.3M |
| Discontinued Ops | $0 | $0 |
| Net Income | $-5.2M | $-5.3M |
| Minority Interest | $0 | $0 |
| Net to Common | $-5.2M | $-5.3M |
| Metric | 2022 | 2023 |
|---|---|---|
| Cash & Equivalents | $222.7K | — |
| Total Assets | $409.8K | $195.2K |
| Accounts Payable | $680.3K | $1.5M |
| Taxes Payable | $128.0K | $132.6K |
| Total Liabilities | $13.0M | $15.8M |
| Shareholders' Equity | $-12.6M | $-15.6M |
| Paid-In Capital | $23.7M | $26.0M |
| Retained Earnings | $-36.3M | $-41.7M |
| Total L&E | $409.8K | $195.2K |
| Metric | 2022 | 2023 |
|---|---|---|
| Net Income (CFO) | $-5.2M | $-5.3M |
| Non-Cash Adjustments | $1.0M | $2.4M |
| Working Capital Changes | $1.0M | $523.8K |
| Cash from Operations | $-3.1M | $-2.3M |
| Cash from Investing | $0 | $0 |
| Cash from Financing | $3.3M | $2.1M |
| FX Effect | $0 | $0 |
| Net Change in Cash | $129.6K | $-200.5K |
| Beginning Cash | $93.1K | $222.7K |
| Ending Cash | $222.7K | $22.2K |
Frequently Asked Questions
How does Cell Source, Inc. make money?
The company's operations are concentrated in research and development of immunotherapy products, with no current commercial revenue streams from product sales or licensing. Financial data indicates all costs are absorbed into general and administrative expenses alongside operating expenses related to ongoing clinical trial support. The business model is entirely dependent on external capital raising to sustain its pipeline.
What are the main risks for CLCS?
The company carries a substantial retained earnings deficit of $41.7M, indicating a long history of losses that must be addressed through future profitability or further dilution. With zero revenue and negative operating cash flow, there is a high risk of liquidity constraints if financing markets tighten. The absence of current income and gross profit exposes the firm to significant valuation volatility typical of early-stage biotech assets.
What is CLCS's competitive advantage?
The company holds proprietary cell therapy platforms that may offer novel mechanisms of action against various cancers compared to standard-of-care therapies. A strong track record of securing significant paid-in capital suggests an ability to attract investor interest despite pre-revenue status. The management team possesses specialized expertise in navigating the complex regulatory landscape of biotechnology development.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.